ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
Natco Pharma Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Natco Pharma issued the notice for its 43rd Annual General Meeting to be held on September 30, 2026, covering agenda items including director appointment and fund-raising.
Natco Pharma filed its Annual Report for FY 2025-26 as required under SEBI regulations. The 43rd AGM is scheduled for September 30, 2026.
Natco Pharma Limited has scheduled a board meeting for September 9, 2026, to discuss potential fund-raising proposals.
NATCO reported Q1 FY27 consolidated revenue of INR 794.4 Cr and PAT of INR 206.5 Cr. Performance was driven by base business growth and a strong flu season at associate Adcock Ingram.
Natco reported a sharp revenue decline due to lower Revlimid contributions, masked by strong growth in Brazil and domestic segments.
Natco Pharma reported Q1 FY27 revenue of INR 7,944 Mn and Net Profit of INR 2,065 Mn. Strategy focuses on high-barrier US formulations and NCE/Cell & Gene therapy investments.
Natco Pharma Ltd reported revenue from operations of ₹735.2 Cr (-44.7% YoY) and net profit of ₹206.5 Cr (-57.0% YoY) for Q1 FY27.
Natco Pharma reported Q4 FY26 revenue of ₹816.9cr and PAT of ₹269cr. The company is diversifying into Brazil, Canada, and South Africa to counter Revlimid decline.
Natco Pharma faces a sharp transition as Revlimid-led super-profits decline, shifting focus to Brazil and Canada. Management guides for a significant 50% profit contraction in FY27 as it attempts to diversify earnings.
Natco Pharma reported FY26 revenue of INR 43,759 Mn and PAT of INR 14,185 Mn, driven by US generic launches and high export formulation contributions.
Natco Pharma Ltd reported revenue from operations of ₹739.1 Cr (-39.5% YoY) and net profit of ₹269 Cr (-33.7% YoY) for Q4 FY26.